Pathos Launches Precision Oncology Pipeline With License of First Phase I Program, a CBP/p300 Inhibitor
Pathos obtains worldwide rights from Novo Nordisk for the development of CBP/p300 inhibitor, FT-7051 Chicago – Pathos AI, Inc. (www.pathos.com), a biotechnology company focused on revolutionizing precision medicine in cancer by harnessing the power of machine learning to transform drug...
Read More
Re-engineering Drug Development for Precision Medicine
There’s no worse feeling than watching a loved one fight bravely through a cancer diagnosis and battle through treatments while hoping for a miracle or a little more time. Suddenly, your doctor tells you that there's nothing more they can...